News articles about Lexicon Pharmaceuticals (NASDAQ:LXRX) have trended somewhat positive on Saturday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1716586907068 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- 1281 Shares Of Lexicon Pharmaceuticals, Inc. (LXRX) bought By AMOUYAL PHILIPPE – Economic News (economicsandmoney.com)
- What the Chart Means for Lexicon Pharmaceuticals, Inc. (LXRX) – Economic News (economicsandmoney.com)
- See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. (finance.yahoo.com)
- Lexicon Pharma, Sanofi Tout More Positive Phase III Diabetes Drug Data (biospace.com)
- Lexicon Pharmaceuticals, Inc. (LXRX) registers a price change of 1.85% while Misonix, Inc. (MSON) finishes with a … – Stocks Gallery (stocksgallery.com)
LXRX has been the subject of a number of recent analyst reports. HC Wainwright set a $27.00 price target on shares of Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $27.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm had revenue of $12 million for the quarter, compared to analysts’ expectations of $18.34 million. During the same quarter last year, the company earned ($0.37) EPS. The firm’s revenue for the quarter was down 40.3% compared to the same quarter last year. On average, analysts expect that Lexicon Pharmaceuticals will post ($1.45) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/19/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-lexicon-pharmaceuticals-lxrx-share-price-updated-updated.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
What are top analysts saying about Lexicon Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lexicon Pharmaceuticals Inc. and related companies.